Value of GLP-1 receptor agonists versus long-acting insulins for type 2 diabetes patients with and without established cardiovascular or chronic kidney diseases: A model-based cost-effectiveness analysis using real-world data
Main finding · Cost per QALY gained, overall cohortResult — go to the resultCost per QALY gained $6,053Authors' conclusion
Using GLP-1RAs versus LAIs for T2D patients represented good economic value in real-world practice. Pronounced economic benefits of GLP-1RA therapy among those with prior CVDs or CKDs support rational treatment decisions and optimal healthcare resource allocation for these patients.
Study context
- Population
- Patients with T2D; inputs from Taiwan's National Health Insurance Research Database or published literature on Taiwanese T2D populations
- Comparison
- GLP-1 RAs vs long-acting insulins
- Outcome
- Healthcare costs (US$) and quality-adjusted life-years (QALYs); cost per QALY gained
- Follow-up
- 10 years
Methodological detailsMarkov model, 10-year horizon, healthcare sector perspective, real-world data
- Markov model
- 10-year horizon
- Healthcare sector perspective
- Real-world data
Main finding
Cost per QALY gained, overall cohort
Cost per QALY gained
$6,053
As reported in the abstract
Further findings
| Outcome | Estimate |
|---|---|
| Subgroup: established CVDs | saved (cost-saving) $673 |
| Subgroup: established CKDs | cost per QALY gained $1,675 |
| Subgroup: without established CVDs | cost per QALY gained $9,093 |
| Subgroup: without established CKDs | cost per QALY gained $7,659 |
Original publication
Value of GLP-1 receptor agonists versus long-acting insulins for type 2 diabetes patients with and without established cardiovascular or chronic kidney diseases: A model-based cost-effectiveness analysis using real-world data. Diabetes Res Clin Pract. Published 15 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →